Under the Paperwork Reduction Act of 1995, no persons are require	U.S. Patent and Treder ed to respond to a collection of informat	nark Office; U.S. DEPARTMENT OF COMMERCE ion unless it contains a valid OMB control number.
Request	Application Number	10/655,854
for Continued Examination (RCE) Transmittal	Filing Date	September 5, 2003
	First Named Inventor	Rafael Reif
Address to: Mail Stop RCE	Art Unit	2826
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Examiner Name	Leonardo Andujar
	Attorney Docket Number	MIT-136AUS
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) or page 2.		
1. Submission required under 37 CFR .1.14 Note: If the RCE is proper, any previously filed unestered amendments and smendments enclosed with the RCE will be netted in the corter in which they were filed unless applicant should otherwise, if applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).		
a. Previously submitted. If a final Office ection is outstending, eny amendments filed efter the final Office action may be considered as a submission even if this box is not checked.		
i. Consider the arguments in the Appeel Brief or Rely Brief previously filed on ii. Other		
b. Finched		
I. 🗸 Amendment/Reply iii. 🔲 Information Disclosure Statement (IDS)		
ii. Affidavit(s)/ Declaration(s) iv. Other		
Miscellaneous Supernsion of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of		
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-0845		
i. RCE fee required under 37 CFR 1.17(e)		
II. Extension of time fee (37 CFR 1.136 and 1.17)		
iii. Other		
b. Amount of \$ 905 the Director is hereby authorized to charge dep. acct. no 50-0845.		
c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not		
be-included on this form. Provide credit card information and authorization on PTO-2038.		
SIGNATURE OF APPLICAN Name (Print/Type) Christopher S. Dawl	IT, ATTORNEY, OR AGENT REQ	UIRED on No. (Attorney/Agent) 37,303
Signature / / Signature	Date	20 TUNO 6
CERTIFICATE OF MAILING OR TRANSMISSION		
hereby contify that this comspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope didressed to: Mall Sbp RCE, Commissioner for Petents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark office on the date shown bejam.		
leme (Print Type) Christopher S. Patr 1 ho		
his collection of information is required by 37 CMR 1.114. The information	Date	20JUNO6
his collection of information is required by 37 CMR 1.114. The information	is required to obtain or retain a benefit	by the public which is to file (and by the USPTO

to process) an applicable. Confidentiality is governed by 30 U.S.C. 122 by 75 CFR 11.4. This collection is estimated to state 12 mixed are generally explained to process and submitted to the 12 mixed are generally explained, preprinting, and submitting the completed application form. The USPTCI Turns well very depending upon the individual case. Any comments on the end of the 12 mixed are submitted to complete this form and/or suggestions for reducing hits burden, sold to sent to the Client Information Officer, U.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Destination of Client (1.S. Patient and Trademark Office, U.S. Patie